Table 2. Factors associated with presence of cancer pain.
TOTAL (N = 402) | EXISTENCE OF CANCER PAIN |
|||||||||
---|---|---|---|---|---|---|---|---|---|---|
No (N = 328) | Yes (N = 74) | |||||||||
N | % | N | % | N | % | p | ||||
Any psychotropic use | ||||||||||
No | 321 | 79.9 | 277 | 84.5 | 44 | 59.5 | <0.001* | |||
Yes | 81 | 20.2 | 51 | 15.5 | 30 | 40.5 | ||||
Anxiolytic use | ||||||||||
No | 334 | 83.1 | 284 | 86.6 | 50 | 67.6 | <0.001* | |||
Yes | 68 | 16.9 | 44 | 13.4 | 24 | 32.4 | ||||
Type of anxiolytic | ||||||||||
Long-acting benzodiazepines | 22 | 32.4 | 18 | 40.9 | 4 | 16.7 | 0.041* | |||
Short-acting benzodiazepines | 46 | 67.7 | 26 | 59.1 | 20 | 83.3 | ||||
Hypnotic use | ||||||||||
No | 384 | 95.5 | 319 | 97.3 | 65 | 87.8 | 0.004*** | |||
Yes | 18 | 4.5 | 9 | 2.7 | 9 | 12.2 | ||||
Type of hypnotic | ||||||||||
Benzodiazepines | 9 | 50.0 | 5 | 55.6 | 4 | 44.4 | >0.005**** | |||
Other | 9 | 50.0 | 4 | 44.4 | 5 | 55.6 | ||||
Antidepressant use | ||||||||||
No | 385 | 95.8 | 314 | 95.7 | 71 | 96.0 | 0.934* | |||
Yes | 17 | 4.2 | 14 | 4.3 | 3 | 4.1 | ||||
Type of antidepresant | ||||||||||
SSRIs a | 17 | 100.0 | 14 | 100.0 | 3 | 100.0 | ||||
Potential confounders | ||||||||||
Gender | ||||||||||
Female | 231 | 57.5 | 197 | 60.1 | 34 | 46.0 | 0.027* | |||
Male | 171 | 42.5 | 131 | 39.9 | 40 | 54.1 | ||||
Age (year), mean [SD] b | 61.17 | [13.14] | 61.14 | [13.50] | 61.30 | [11.53] | 0.845** | |||
Marital status | ||||||||||
Married | 276 | 77.7 | 229 | 79.5 | 47 | 70.1 | 0.150* | |||
Single | 50 | 14.1 | 40 | 13.9 | 10 | 14.9 | ||||
Divorced/Separated | 11 | 3.0 | 7 | 2.4 | 4 | 6.0 | ||||
Widowed | 18 | 5.1 | 12 | 4.2 | 6 | 9.0 | ||||
Missing | 47 | 11.7 | 40 | 12.2 | 7 | 9.5 | ||||
Children | ||||||||||
No | 88 | 24.8 | 69 | 24.0 | 19 | 28.4 | ||||
Yes | 267 | 75.2 | 219 | 76.0 | 48 | 71.6 | 0.457* | |||
Missing | 47 | 11.7 | 40 | 12.2 | 7 | 9.5 | ||||
Number of children, mean [SD] b | 1.83 | [1.01] | 1.82 | [1.04] | 1.90 | [0.93] | 0.437** | |||
Educational level | ||||||||||
Primary | 202 | 57.5 | 166 | 58.2 | 36 | 54.5 | 0.410* | |||
Secondary | 80 | 22.8 | 61 | 21.4 | 19 | 28.8 | ||||
University | 69 | 19.7 | 58 | 20.4 | 11 | 16.7 | ||||
Missing | 51 | 12.7 | 43 | 13.1 | 8 | 10.8 | ||||
Type of cancer (location) | ||||||||||
Breast | 111 | 27.6 | 98 | 29.9 | 13 | 17.6 | <0.001* | |||
Rectal | 64 | 15.9 | 56 | 17.1 | 8 | 10.8 | ||||
Lung | 37 | 9.2 | 21 | 6.4 | 16 | 21.6 | ||||
B-cell lymphoma | 30 | 7.5 | 27 | 8.2 | 3 | 4.1 | ||||
Ovary | 14 | 3.5 | 12 | 3.7 | 2 | 2.7 | ||||
Other | 146 | 36.3 | 114 | 34.8 | 32 | 43.2 | ||||
Cancer therapy | ||||||||||
Chemotherapy | ||||||||||
No | 37 | 9.2 | 32 | 9.8 | 5 | 6.8 | 0.420* | |||
Yes | 365 | 90.8 | 296 | 90.2 | 69 | 93.2 | ||||
Radiotherapy | ||||||||||
No | 224 | 55.7 | 190 | 57.9 | 34 | 45.9 | 0.061* | |||
Yes | 178 | 44.3 | 138 | 42.1 | 40 | 54.1 | ||||
Hormone therapy | ||||||||||
No | 346 | 86.1 | 277 | 84.5 | 69 | 93.2 | 0.048* | |||
Yes | 56 | 13.9 | 51 | 15.5 | 5 | 6.8 | ||||
Biological therapy | ||||||||||
No | 278 | 69.2 | 226 | 68.9 | 52 | 70.3 | 0.818* | |||
Yes | 124 | 30.8 | 102 | 31.1 | 22 | 29.7 | ||||
Surgery | ||||||||||
No | 212 | 52.7 | 167 | 50,9 | 45 | 60.8 | 0.124* | |||
Yes | 190 | 47.3 | 161 | 49.1 | 29 | 39.2 | ||||
Side effects of cancer treatment | ||||||||||
No | 83 | 20.6 | 79 | 24.1 | 4 | 5.4 | <0.001* | |||
Yes | 319 | 79.4 | 249 | 75.9 | 70 | 94.6 | ||||
Analgesic | ||||||||||
No | 330 | 82,1 | 328 | 100 | 2 | 2.7 | <0.001* | |||
Yes | 72 | 17.9 | 0 | 0 | 72 | 97.3 | ||||
Effectiveness of analgesia | ||||||||||
Adequate pain control | 33 | 45.8 | 0 | 0 | 33 | 45.8 | ||||
Inadequate pain control | 39 | 54.2 | 0 | 0 | 39 | 54.2 | ||||
Fatigue | ||||||||||
No | 206 | 51.2 | 165 | 50.30 | 41 | 55.4 | 0.507* | |||
Yes | 196 | 48.8 | 163 | 49.69 | 33 | 44.6 |
a SSRIs: selective serotonin reuptake inhibitors
b Standard deviation
*Compared using chi-square test
**Compared using Wilcoxon two-sample test
***Compared using LR chi-square test
****Compared using Fisher exact test